2019年11月29日星期五

Today's New Buy Pick - Catabasis Pharmaceuticals, Inc. (CATB)

Black Friday May Have Just Started But One Analyst Says These 3 Stocks Are Already Winning The Holiday

Black Friday may have just started, but according to Citigroup analyst Paul Lejuez, the day has already been won by three stocks. "Let's be honest. We can easily write [the holiday review] now – actually we wrote most of this a year ago," Lejuez wrote in a research report. "Here's what we would have written in a Monday review note after Thanksgiving weekend if we didn't write it today." The analyst is bullish on Target, Five Below, and T.J. Maxx parent TJX Companies for this holiday season. 

Tech Data shares are up more than 12% this morning following reports that the company has agreed to be bought by private-equity firm Apollo Global Management for $145, valuing the tech company at $5.14 billion, after an unnamed suitor topped Apollo's original offer of $130 per share with a bid of $140.    

The stock market crashed 89% back in 1929… and it can happen again. But options give you the potential to go after profit even when the market crashes. Getting started is simple.  (ad)
 

If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval. (ad)
 
PVH has rallied 10% in six weeks – but it's still a big bargain

I suppose it's appropriate that on Thanksgiving – the day retailers like to think of as "the day before Black Friday" – I'm focusing today on a company in the Consumer Discretionary sectors that produces many of most well-known apparel brands in the country. The last month has led the market to rally on the expectation that a trade deal will be reached sooner than later.

The Fed continues to show an accommodative hand (even if the White House doesn't seem to agree) in its approach to interest rates, and most economic indicators seem to be mostly favorable as well. That seems to have many investors buying into the "Goldilocks" economic target the Fed always talks about trying to hit – it's neither too hot, nor too warm, but running along just right and should continue to do so for the foreseeable future.

 
Legendary investor Jeff Brown believes 10% of the world's population will be buying this new technology by the end of the year... (ad)
Featured Stock

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States.

The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing CAT-5571 for the treatment of cystic fibrosis.
Other Top Stories
   
  
 
Sponsor

Small cap stocks offer investors the potential for more significant upside and faster growth. This Special Report details 3 top small cap stocks poised for fast-moving growth potential through the rest of 2019.
 
Trend Following Picks
 


Reversal Picks
 
Already subscribed to our premium service?


Not a TradersPro subscriber yet?

 
                                                           



This email was sent to its028@gmail.com by Investiv, LLC
265 N. Main | Ste. D #283 | Kaysville | UT | 84037
Forward to a friend | Unsubscribe or Mange which emails you get from TradersPro

Disclaimers

Investing is Inherently Risky

There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses.

Hypothetical Results Are Reported

Results and examples used in the Company's advertisements, books, videos, websites, and other media—including on the Site and the Network—are, in some cases, based on hypothetical (simulated) trades. Plainly speaking, these trades were not actually executed. Hypothetical performance results have certain limitations. Unlike an actual performance record, hypothetical results do not represent actual trading. Also, since the trades have not been executed, the hypothetical results may have under-or-over compensation for the impact, if any, of certain market factors, such as lack of liquidity. Hypothetical trading programs generally are also subject to the fact that they are designed with the benefit of hindsight. Hypothetical results also do not account for commissions or slippage.

The Company's simulations assume purchase and sale prices believed to be attainable. Yet traders are going to be getting into trades at different times and using various exit approaches, which may result in different pricing and outcomes. You may or may not receive the best available price on the purchase or the sale of a position in actual trading.

Information provided by the Company is not investment advice. The Company is not a registered investment adviser, stock broker, or brokerage. You agree that the Company does not represent, warrant, or take responsibility that any account will or is likely to achieve profit or losses similar to those shown. Examples published by the Company are selected for illustrative purposes only. They are not typical and do not represent the typical results of all stocks within the Company's software or its individual scans and searches. No independent party has audited any hypothetical performance contained at this Web site, nor has any independent party undertaken to confirm that they reflect the trading method under the assumptions or conditions specified.

Offers Disinterested Commentary and Analysis

The Company does not receive any form of payment or other compensation for publishing information, news, research, or any other material concerning specific securities on the Network that is intended to affect or influence the value of securities. The Company, and its personnel, do not engage in front-running of recommendations and do not trade against one's own recommendations.

The Company and its management may benefit from an increase or decrease in the share prices of the profiled companies, and/or may have other actual or potential conflicts of interest. If a particular security featured in a newsletter publication is concurrently owned by the Company in its corporate brokerage account, or in any of the individual accounts of the Company's principals or analysts / writers, that fact will be disclosed. The Company, its principals, analysts and writers may choose to purchase a security or derivative featured in one of its newsletter publications, but typically will wait three (3) trading days from the date of publication before initiating said purchase.

Disclaimers, Terms & Conditions | Privacy Policy

Copyright © 2019
发帖者 时间：

没有评论:

发表评论

订阅： 博文评论 (Atom)